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Abstract
Background.Autism spectrum disorders (ASDs) and schizophrenia spectrum disorders (SSDs),
although conceptualized as separate entities, may share some clinical and neurobiological
features. ASD symptoms may have a relevant role in determining a more severe clinical
presentation of schizophrenic disorder but their relationships with cognitive aspects and
functional outcomes of the disease remain to be addressed in large samples of individuals.
Aims.To investigate the clinical, cognitive, and functional correlates of ASD symptoms in a large
sample of people diagnosed with schizophrenia.
Methods. The severity of ASD symptoms was measured with the PANSS Autism Severity Scale
(PAUSS) in 921 individuals recruited for the Italian Network for Research on Psychoses
multicenter study. Based on the PAUSS scores, three groups of subjects were compared on a
wide array of cognitive and functional measures.
Results. Subjects withmore severe ASD symptoms showed a poorer performance in the processing
speed (p=0.010), attention (p=0.011), verbal memory (p=0.035), and social cognition (p=0.001)
domains, and an overall lower global cognitive composite score (p=0.010). Subjects with more
severe ASD symptoms also showed poorer functional capacity (p=0.004), real-world interpersonal
relationships (p<0.001), and participation in community-living activities (p<0.001).
Conclusions. These findings strengthen the notion that ASD symptoms may have a relevant
impact on different aspects of the disease, crucial to the life of people with schizophrenia.
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Introduction
Background
Autism spectrum disorders (ASDs) and schizophrenia spectrum
disorders (SSDs) are currently conceptualized as separate nosolog-
ical entities [1]. However, this dichotomic separation has been
called into question, as the two spectra show many similarities,
and their overlap has recently been the focus of a growing body of
literature [2–7]. In fact, one of the earliest conceptualizations of
schizophrenia, redacted by Eugen Bleuler over a century ago [8],
already described autistic features as a central element of the
disorder, and only later was ASD defined as a distinct entity.
Deficits in social cognition and social interactions are key fea-
tures of both ASDs and SSDs [9,10], and different brain imaging
and genetic studies suggest that the two spectra might share similar
aspects not only at a clinical level but also at a neurobiological,
pathophysiological, and etiopathogenetic levels [11–15].
ASDs symptoms are more frequent in people diagnosed with
schizophrenia than in healthy subjects [16,17], and, in people with
SSDs, more severe ASD symptoms emerged as predictors of poorer
performance on differentmeasures of social cognitive abilities, both
in the emotion processing and in the mental state attribution/
theory of mind domains [18]. Prominent ASD symptoms have also
been linked to poorer real-world functioning and greater impair-
ments in the ability to judge the quality of everyday functioning
[19].
Furthermore, a recent study investigating cognitive and clinical
correlates of ASD symptoms in schizophrenia has found that
people with a clear diagnosis of schizophrenia and prominent
ASD symptoms showed a lower IQ and a poorer performance in
a number of cognitive domains, including processing speed, work-
ing memory, and executive functions, leading to the interesting
hypothesis that these subjects diagnosed with schizophrenia may
represent a subpopulation, with specific clinical characteristics
[20]. In addition, another study demonstrated a poorer response
to antipsychotic treatment in first-episode early-onset psychosis
patients with ASD, compared to those without ASD [21].
Thus, the investigation of the presence of ASD symptoms in
people diagnosed with schizophrenia represents an interesting and
important issue for the study of the illness itself and for the
development of more tailored interventions. However, the most
used diagnostic instruments available for the assessment of ASD,
namely the autism diagnostic observation schedule (ADOS) [22]
and the autism diagnostic interview-revised (ADI-R) [23], may not
represent a viable solution for the assessment of ASD symptoms in
people with schizophrenia, due to the complexity and time required
for their application. Recently, the PANSS Autism Severity Score
(PAUSS) [24], a scale derived from the Positive and Negative
Syndrome Scale (PANSS) [25], has been developed and demon-
strated to be an easy and reliable instrument for the assessment of
ASD symptoms in people diagnosed with schizophrenia in the
clinical practice.
A recent study [26] confirmed, in a small sample of patients
recruited for a cognitive remediation study, that the PAUSS repre-
sents a valid and practical instrument for the assessment of ASD
symptoms in people diagnosed with schizophrenia, comparable to
more established but more complex and time-consuming tools as
the ADOS and the ADI-R. Moreover, using the PAUSS cut-off
score for “autistic schizophrenia” [24], it was possible to identify a
subgroup of patients with schizophrenia and ASD symptoms,
characterized by a lower IQ, poorer neuro- and socio-cognitive
performance, and poorer real-world functioning. Although being
of both theoretical and clinical interest, these findings have to be
replicated in larger samples, better representing the population of
people diagnosed with schizophrenia.
Aims
The aim of the present study was to further investigate the clinical,
cognitive, and functional correlates of ASD symptoms, as assessed
with the PAUSS, in a large sample of people diagnosed with
schizophrenia, recruited in the real-world multicenter study of
the Italian Network for Research on Psychoses. In particular, the
study compared subjects with low, moderate, and prominent ASD
symptoms, as defined by the PAUSS cut-off scores for nonautistic
and autistic schizophrenia, on demographic and clinical variables




For this study, the database of the Italian Network for Research in
Psychoses was used. It includes 921 individuals diagnosed with
schizophrenia (280 females, mean age 40.17 10.71).
The ItalianNetwork for Research in Psychoses is a large research
network including 26 Italian University Psychiatric Clinics and
Mental Health Departments, providing data on a large number of
people diagnosed with schizophrenia living in the community that
has been assessed with a wide array of clinical, cognitive, and
functional measures [27,28].
Participants were recruited from March 1, 2012 to September
30, 2013.
Inclusion criteria were: (a) diagnosis of schizophrenia according
to DSM-IV TR criteria [29] confirmed with the structured clinical
interview for DSM-IV-patient version (SCID-I-P) [30] and (b) age
between 18 and 66 years. Exclusion criteria were: (a) history of head
trauma with loss of consciousness; (b) history of moderate to severe
mental retardation or of neurological diseases; (c) history of alcohol
and/or substance abuse in the last 6months; (d) current pregnancy
or lactation; (e) inability to provide informed consent for partici-
pation in the study; (f) treatment modifications and/or hospitali-
zation due to symptom exacerbation in the last 3months.
According to the same procedure in all centers, enrolled patients
completed the assessments in 3 days with the following schedule:
collection of sociodemographic information, psychopathological
evaluation, and neurological assessment on day 1, in the morning;
assessment of neurocognitive functions, social cognition, and func-
tional capacity on day 2, in the morning; assessment of personal
resources and perceived stigma either on day 3 (morning or after-
noon) or in the afternoon of day 1 or 2, according to the patient’s
preference. For real-life functioning assessment, patient’s key care-
giver was invited to join one of the scheduled sessions.
Out of 1,691 screened patients, 1,180 were eligible; of these,
202 refused to participate, 57 dropped out before completing the
procedures, and 921 were included in the analyses.
All included subjects provided written informed consent to
participate after receiving a comprehensive explanation of study
procedures and goals. The study protocol was approved by the
Ethical Committee of the coordinating center and of the other
participating centers (approval number 73/2012).
Demographic and clinical characteristics of the sample are
reported in Table 1.
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Measures
Clinical assessment
Demographic and clinical data for each subject were collected from
different sources, such as family members, medical records, and
mental health worker reports.
The PANSS [25] was used for the assessment of symptoms
severity. The PANSS is a semistructured interview composed by
30 items divided in three subscales, namely positive symptoms,
negative symptoms, and general psychopathology. Each item is
accompanied by a specific definition and by detailed anchoring
criteria for each rating point, ranging from “absent” (1) to “severe” (7).
ASD symptoms assessment
In order to assess the severity of ASD symptoms, the PANSS
Autism Severity Scale (PAUSS) [24] was derived from the
PANSS and calculated by performing the sum of the following
PANSS items: N1 (“blunted affect”), N3 (“poor rapport”),
N4 (“social withdrawal”), N5 (“difficulties in abstract thinking”),
N6 (“lack of spontaneity and flow of conversation”), N7 (“stereo-
typed thinking”), G5 (“mannerism”), and G15 (“preoccupation”).
The PAUSS validity in identifying ASD symptoms in people diag-
nosed with schizophrenia has been already demonstrated and
found to be satisfying, with the PAUSS strongly correlating with
other more established diagnostic tools for the assessment of ASD
and showing even better sensitivity than such scales in detecting
ASD symptoms in people with schizophrenia [26].
According to the results of the original validation study of the
PAUSS [24], subjects were divided into three different groups, based
on the PAUSS total score: subjects with “autistic schizophrenia”
(PAUSS ≥30), subjects with “nonautistic schizophrenia” (PAUSS
≤10), and subjects with “moderate ASD symptoms” (PAUSS
between 11 and 29). These cut-off scores have been identified and
validated by the scale authors in a large sample of individuals
diagnosed with schizophrenia and have been reported in the scale
validation study [24].
Cognitive assessment
Cognitive performance was assessed using theMATRICS consensus
cognitive battery (MCCB) [31]. The MCCB is composed by specific
tasks assessing the following cognitive domains: speed of processing
(Trail Making Test Part A; Brief Assessment of Cognition in Schizo-
phrenia: Symbol Coding; Category Fluency Test: Animal Naming),
verbal and spatial learning (Hopkins Verbal Learning Test-Revised,
immediate recall; Brief Visuospatial Memory Test-Revised), reason-
ing and problem solving (Neuropsychological Assessment Battery,
Mazes subtest), attention (Continuous Performance Test: Identical
Pairs), working memory (Wechsler Memory Scale, Spatial Span
subset; Letter Number Span Test), and social cognition (Mayer–
Salovey–Caruso Emotional Intelligence Test: Managing Emotion
task). A t-score was computed for each cognitive domain, corrected
by gender, age, and education, and a global cognitive composite score
was finally calculated following the recommendation of the battery
developers [32].
Functional outcomes measures
Functional capacity was assessed with the UCSD performance-
based skills assessment, brief (UPSA-B) [33]. The UPSA-B is a brief
and widely used performance-based instrument that assesses skills
involved in community tasks: “financial skills” (e.g., counting
money and paying bills) and “communication skills” (e.g., to dial
a telephone number for emergency or reschedule an appointment
by telephone), with a total score ranging from 0 to 100.
Real-world functioning was assessed using the Specific Level of
Functioning Scale (SLOF), an informant-rated measure that
explores different aspects of functioning and is based on the key
caregiver’s judgment on behavior and functioning of patients
[34]. It consists of 43 items, divided into six different scales,
including the following domains: physical efficiency, skills in self-
care, interpersonal relationships, social acceptability, participation
in community activities (e.g., shopping, using public transporta-
tion), and working abilities. Each item is rated from 1 to 5, with
higher scores indicating better functioning. The SLOF has been
found to be a reliable and valid instrument to assess real-world
functioning in people diagnosed with schizophrenia, with good
construct validity and internal consistency, and has been recently
validated in Italian [35].
Data collection and handling
Comparability of data collection procedures was assured by a
centralized training of all the researchers, before starting recruit-
ment and assessments. For each category of variables (psychopa-
thology, including diagnosis, illness-related factors, cognition, real-
life functioning, personal resources, and context-related factors), at
least one researcher per site was trained. In order to avoid halo
effects, the same researcher could not be trained for more than one
category. The interrater reliability was formally evaluated by
Cohen’s kappa for categorical variables and intraclass correlation
coefficient (ICC) or percentage agreement for continuous variables.
An excellent interrater agreement was found for the SCID-I-P
(Cohen’s kappa 0.98). Good to excellent agreement among raters
was observed for SLOF (ICC 0.55–0.99, percentage agreement
70.1–100%); PANSS (ICC 0.61–0.96, percentage agreement 67.7–
93.5%); and MCCB (ICC 0.87).
Assessment was conducted within 2weeks after subjects’
recruitment.
In the database of the study, fields for all variables were exactly
corresponding to those of paper forms on which data were col-
lected. For variables with finite domain and low cardinality, raw
data were inputted to the database by means of drop-down menu
showing the possible relevant options, while for a minority of
variables, with finite domain and high cardinality or with bounded
Table 1. Characteristics of the sample (N = 921).
Variable %, MeanSD
Gender (% females) 30.40
Age (years, meanSD) 40.17 10.71
Education (years, meanSD) 11.61 3.43
Work (% employed) 29.23
Age at first psychotic episode (years, meanSD) 24.02 7.19
Previous hospitalization (% yes) 68.39
Number of previous hospitalizations (MeanSD) 3.77 4.33
Complete remission at first episode (% yes) 38.26
Suicide attempt, lifetime (% yes) 17.12
Previous alcohol abuse (% yes) 16.41
Previous substance abuse (% yes) 25.95
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domain, digits were typed in the database. In both cases, the system
verified that the input was admissible against extreme values. For
cases in which admissibility was not verifiable (e.g., a variable for
which high values are still possible although improbable), the
quality control periodically performed for all variables allowed to
identify outlier values that were then checked against data on paper.
Data of subjects were associated to a pseudonym (ID code), and
the correspondence between ID code and the subject was on an off-
system paper form located at the site that recruited the subject. Data
in transit between the remote location and the server were
encryptedwith the end-to-end coding. A full backup of the database
was performed everyday and signed off.
All participants signing the informed consent to participate in
the study gave their authorization to publication of results in
scientific journals. No deadline for data analysis or publication
was specified in the informed consent.
Statistical analyses
The three groups of subjects identified using the PAUSS cut-off
scores were compared on demographic, clinical, cognitive, and
functional measures. The distribution of scores of each considered
variable was inspected for normality and for homogeneity of var-
iance in order to allow the use of parametric statistics.
Dichotomous variables were analyzed using Pearson’s χ2 tests,
with results reported as percentages. Continuous variables were
analyzed with general linear model analyses of co-variance
(ANCOVAs). A construct calculated by subtracting the PAUSS
total score from the PANSS total score (PANSSminus PAUSS) was
included as a covariate in the analyses of cognitive performance and
functioning, in order to rule out the possibility that the PAUSS
could represent and indirect proxy of global symptoms severity.
This construct was introduced in the analyses instead of the total
PANSS score in order to avoid collinearity with the PAUSS, as
detailed in a previous study on the role of ASD symptoms in people
with schizophrenia [18]. Age and education were also included as
covariates in the analyses on functioning but not in the analyses
regarding cognitive performance, since cognitive performance vari-
ables were already corrected by gender, age, and education. Post-
hoc, between-groups analyses were performed accounting for
multiple comparisons using Bonferroni correction.
Statistical analyses were performed using SPSS 15.0. p-Values
<0.05 (two tailed) were considered significant.
Results
Prevalence of ASD symptoms
The mean PAUSS total score was 22.89 (SD 8.26). One hundred
and eighty-five subjects (20.11% of the total sample) had a PAUSS
≥30 and thus were included in the “autistic schizophrenia” group;
56 subjects (6.09%) had a PAUSS≤10 and thus were included in the
“nonautistic schizophrenia” group; 679 (73.80%) had a PAUSS
between 11 and 29 and thus were included into the “moderate
ASD symptoms” group.
Between-groups comparisons of demographic variables
For demographic variables (Table 2), significant between-groups
differences emerged for age (p<0.001), with “nonautistic
schizophrenia” subjects being younger than “autistic schizophrenia”
(p<0.001) and then “moderate ASD symptoms” patients (p=0.003),
education (p=0.001), with “autistic schizophrenia” subjects showing
fewer years of education compared to “moderateASD symptoms” (p
=0.010) and to “nonautistic schizophrenia” subjects (p=0.004), and
employment (p=0.004), with a larger proportion of unemployed
subjects in the “autistic schizophrenia” group, compared to “mod-
erateASD symptoms” (p=0.009) and to “nonautistic schizophrenia”
(p=0.009) groups. No differences emerged for gender distribution
among groups.
Between groups comparisons of clinical variables
For clinical variables (Table 2), significant between-groups differ-
ences emerged in the rate of individuals having previous hospital-
izations (p=0.022), which were lower in the group of “nonautistic
schizophrenia” compared with the “moderate ASD symptoms”
subjects (p= 0.018). A complete remission at first episode was also
different between-groups (p< 0.001) and was achieved more fre-
quently in “nonautistic schizophrenia” subjects, compared to the
“autistic schizophrenia” (p< 0.001) and to the “moderate ASD
symptoms” group (p< 0.001); the latter showing still significantly
higher remission rate than that of the “autistic schizophrenia”
group (p=0.024). No between-groups differences emerged for
age at first psychotic episode, number of previous hospitalizations,
previous suicide attempts, and previous alcohol and substance
abuse.
Between groups comparisons of cognitive performance
Between-groups comparisons of cognitive measures (Table 3) were
covaried by nonautistic symptoms severity (PANSS minus
PAUSS). Significant between-groups differences at the ANCOVAs
were observed on different cognitive domains, in particular on
processing speed (p=0.010), attention (p= 0.011), verbal memory
(p=0.035), and social cognition (p=0.001). A significant between-
group difference was also observed on the global cognition com-
posite score (p=0.010).
When performing posthoc comparisons, a poorer cognitive per-
formance in the “autistic schizophrenia” group, compared to “non-
autistic schizophrenia” subjects emerged for verbal memory
(p=0.037), social cognition (p=0.002), and global cognition
(p=0.028). A poorer cognitive performance in the “autistic
schizophrenia” group, compared to subjects with “moderate ASD
symptoms,” emerged for processing speed (p=0.010), attention (p=
0.012), and global cognition (p=0.017). A poorer cognitive perfor-
mance in subjects with “moderate ASD symptoms” compared with
“nonautistic schizophrenia” subjects emerged in the social cognition
domain (p=0.001).
No between-groups differences emerged for working memory,
visual memory, and problem solving.
Between groups comparisons of psychosocial functioning
Between-groups comparisons of psychosocial functioning mea-
sures (Table 4) were covaried by age, education, and nonautistic
symptoms severity (PANSS minus PAUSS).
Significant between-groups differences were observed on func-
tional capacity, as measured by the UPSA-B (p= 0.004), on real-
world interpersonal skills, as measured by the SLOF-interpersonal
relationships subscale (p< 0.001), on social acceptability, as mea-
sured by the SLOF-social acceptability subscale (p= 0.019), and on
participation in community activities, as measured by the SLOF-
activities subscale (p< 0.001).
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Looking at the posthoc comparisons, a poorer psychosocial
performance of the “autistic schizophrenia” group compared to
“nonautistic schizophrenia” subjects emerged in different areas, as
measured with the UPSA-B (p=0.021), the SLOF-interpersonal
relationships (p< 0.001) and the SLOF-activities (p=0.013). Also,
a poorer psychosocial performance of the “autistic schizophrenia”
group compared to the “moderate ASD symptoms” group emerged
for the UPSA-B (p= 0.006), the SLOF-interpersonal relationships
(p< 0.001), and the SLOF-activities (p< 0.001). Finally, “moderate
ASD symptoms” subjects showed a poorer psychosocial perfor-
mance than “nonautistic schizophrenia” subjects in the SLOF-
interpersonal relationships (p< 0.001). A better psychosocial per-
formance of the “autistic schizophrenia” group compared to the
“nonautistic schizophrenia” group emerged for the SLOF-social
acceptability (p=0.028). No between-groups differences emerged
in the SLOF-physical functioning, the SLOF-personal care, and the
SLOF-work.
Discussion
The study demonstrated that the cut-off scores of the PAUSS
allowed to identify, among a large and representative sample of
subjects with schizophrenia, three groups of patients with different
clinical, cognitive, and functional characteristics.
The between-groups differences emerged in the neuro- and
social-cognitive measures, as a whole, corroborated the hypothesis
of greater cognitive impairment in people diagnosed with schizo-
phrenia and increasingly prominent ASD symptoms [20,26]. They
are in line with previous findings correlating ASD features and
deficits in neuro- and social-cognition [36–38] and suggest a direct










Variable MeanSD/ %(n) MeanSD/ %(n) MeanSD/ %(n) (p-value) (p-value) (p-value) (p-value)
Gender
Male 62.50 (35) 69.26 (471) 72.97 (135) 0.307 0.891 0.969 0.396
Female 37.50 (21) 30.74 (209) 27.03 (50)
Age (years) 35.30 1.43 40.16 0.41 41.46 0.78 <0.001** 0.003** 0.265 <0.001**
Education (years) 12.55 3.06 11.73 3.46 10.90 3.27 0.001** 0.249 0.010* 0.004**
Work
Employed 39.29 (22) 30.96 (203) 19.89 (36) 0.004** 0.600 0.009** 0.009**
Unemployed 60.71 (34) 69.04 (453) 80.11 (145)
Age at first psychotic
episode (years)
25.08 0.96 24.14 0.27 23.20 0.53 0.149 1.000 0.346 0.260
Previous hospitalization
Yes 51.78 (29) 69.59 (467) 69.06 (125) 0.022* 0.018* 1.000 0.054




2.75 3.63 3.85 4.40 3.75 4.21 0.381 0.497 1.000 0.726
Complete remission at first episode
Yes 65.45 (36) 38.66 (254) 27.71 (46) <0.001** <0.001** 0.024* <0.001**
No 34.55 (19) 61.34 (403) 72.29 (120)
Suicide attempt, lifetime
Yes 16.36 (9) 17.95 (121) 14.28 (26) 0.501 1.000 0.723 1.000
No 83.44 (46) 82.05 (553) 85.72 (156)
Previous alcohol abuse
Yes 19.64 (11) 17.01 (115) 13.18 (24) 0.371 1.000 0.684 0.699
No 80.36 (45) 82.99 (561) 86.82 (158)
Previous substance abuse
Yes 28.57 (16) 27.21 (185) 20.54 (38) 0.167 1.000 0.222 0.810
No 71.43 (40) 72.79 (495) 79.46 (147)
Posthoc comparisons include Bonferroni correction.




relationship between impairment in social cognitive performance
and ASD symptoms severity in people diagnosed with schizophre-
nia [18].
As for functional outcomes, functional capacity and personal
and social functioning impairments were found to progressively
increase with the severity of ASD symptoms. These results confirm
those of previous studies conducted in much smaller samples
[20,26], that hypothesized the existence of a gradient of increasingly
higher impairment in people with schizophrenia with greater levels
of ASD symptoms severity.
Considering real-world functioning, the greater impairment in
interpersonal relationships and participation in community activ-
ities in individuals with more severe ASD symptoms was an
expected result, as deficits in social interactions are one of the key
features of ASD and is in line with previous findings [19].
The use of age, education, and nonautistic symptoms severity
as covariates in the analyses allowed subjects with more prom-
inent ASD features to emerge as the group showing better social
acceptability. This result might at first appear counterintuitive
also considering the raw scores obtained with the scale. In fact,
the between-groups differences, even when corrected by age,
education, and nonautistic symptoms were small in size and
clinically negligible and probably sensitive to the statistic proce-
dure applied. Anyway, it may be well that the usual social
interaction style of ASD individuals, more prone to social retire-
ment, could be perceived to some extent as more socially
Table 3. Group comparison for cognitive measures.







Variable MeanSD MeanSD MeanSD (p-value) (p-value) (p-value) (p-value)
Processing speed (t-score) 35.00  10.91 31.95  11.07 26.96  12.20 0.010* 1.000 0.010* 0.071
Attention (t-score) 40.70  13.90 37.67  11.04 33.06  10.76 0.011* 0.975 0.012* 0.057
Working memory (t-score) 38.61  12.01 35.62  11.45 30.55  12.73 0.087 1.000 0.083 0.442
Verbal memory (t-score) 39.70  11.42 35.44  11.74 31.94  12.88 0.035* 0.234 0.140 0.037*
Visual memory (t-score) 35.54  14.78 32.83  14.42 28.69  15.04 0.590 1.000 0.914 1.000
Problem solving (t-score) 39.91  9.29 38.26  10.25 34.95  9.18 0.088 1.000 0.086 0.409
Social cognition (t-score) 36.69  7.17 32.47  6.98 31.50  7.36 0.001** 0.001** 1.000 0.002**
Global cognition (composite score) 31.47  13.16 26.93  11.43 21.46  12.31 0.010* 0.517 0.017* 0.028*
Raw scores for each variable are reported; all cognitivemeasures are corrected for gender, age, education; all the analyseswere covaried by nonautistic symptoms severity (PANSS–PAUSS). Post-
hoc comparisons include Bonferroni correction.
Abbreviations: Aut-S, autistic schizophrenia; Moderate, moderate ASD symptoms; Non-Aut-S, nonautistic schizophrenia.
*p < 0.05.
**p < 0.01.
Table 4. Group comparison for functional measures.







Variable MeanSD MeanSD MeanSD (p-value) (p-value) (p-value) (p-value)
UPSA-B (functional capacity) 80.12  14.77 69.52  21.22 57.49  22.22 0.004* 0.577 0.006** 0.021*
SLOF: Physical functioning (real-world
physical efficiency)
24.61  0.80 24.28  1.23 23.99  1.77 0.938 1.000 1.000 1.000
SLOF: Personal care (real-world self-care
skills)
33.86  2.19 32.08  3.56 29.58  5.20 0.056 1.000 0.049 0.517
SLOF: Interpersonal relationships
(real-world interpersonal skills)
27.60  6.24 22.83  5.59 18.85  5.93 < 0.001** < 0.001** < 0.001** < 0.001**
SLOF: Social acceptability (real-world social
acceptability)
33.16  3.06 32.57  3.21 31.86  3.45 0.019* 0.312 0.050 0.028*
SLOF: Activities (participation in community
activities)
51.45  5.00 46.93  7.48 40.48  10.38 <0.001* 1.000 <0.001** 0.013*
SLOF: Work (real-world working skills) 23.98  5.59 20.39  6.05 17.33  5.87 0.776 1.000 1.000 1.000
Raw scores for each variable are reported; all the analyses were covaried by age, education, and nonautistic symptoms severity (PANSS–PAUSS). Posthoc comparisons include Bonferroni
correction.
Abbreviations: Aut-S, autistic schizophrenia; Moderate, moderate ASD symptoms; Non-Aut-S, nonautistic schizophrenia; SLOF, Specific Level of Functioning Scale; UPSA-B, UCSD performance-
based skills assessment-brief version.
*p < 0.05.
**p < 0.01.
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acceptable than that of other groups of people diagnosed with
schizophrenia.
No difference between PAUSS subgroups was observed in the
SLOF-work subscale; however, individuals with more prominent
ASD symptoms where more frequently unemployed. This may
reflect both the overall low level of working skills of the entire
sample, as indicated by the SLOF-work subscale, and the fact that
other factors, not directly related to work skills, may interfere with
the possibility to maintain a job in subjects with prominent ASD
symptoms. This is an intriguing perspective that should be better
investigated with specific studies.
In general, our results showed a high prevalence of ASD symp-
toms in people diagnosed with schizophrenia, confirming the
existence of significant areas of overlap between SSDs and ASDs.
They also confirmed the possibility to use the PAUSS, a simple, fast,
and practical tool for the assessment of ASD symptoms in people
diagnosed with schizophrenia, for identifying subgroups of subjects
diagnosed with schizophrenia with increasing ASD symptoms
severity and a parallel gradient of severity of cognitive and psycho-
social functioning impairments. These results corroborate, in a
clinical perspective, those of studies focused on neurobiological
aspects of ASD features in schizophrenia, as the PAUSS has been
recently used in genetic studies for the investigation of the associ-
ation between the autistic genotype and phenotype [39,40], and in
neuroimaging studies, which reported an association between
autistic symptoms and structural and functional imaging features
[41,42].
To our knowledge, this is the first study in which a gradient of
increasingly higher cognitive and functional impairment among
different levels of ASD symptoms severity has been demonstrated
in people diagnosed with schizophrenia.
Among the strengths of the study are the characteristics of the
sample analyzed, composed of a very large group of well-diagnosed
subjects diagnosed with schizophrenia, representative of the het-
erogeneous demographic and clinical characteristics of the Italian
population of people diagnosed with schizophrenia, in the real-
world. Moreover, the cognitive and functioning assessment was
conducted using a wide array of well-validated instruments, allow-
ing a reliable investigation of specific cognitive and functioning
areas.
It is possible that the correlation between ASD symptoms sever-
ity and cognitive and functional deficits might be partially
explained by a longer duration of illness, as individuals in the
“nonautistic schizophrenia” group were younger, and possibly in
an earlier stage of the disorder: therefore, they could have not yet
developed the negative cognitive and functional sequelae, as well as
a more severe clinical condition, which are usually associated with
longer term psychosis. However, by introducing covariates such as
age, education, and nonautistic symptoms severity in the analyses,
we were able to rule out the influence of one or more of such
covariates, thus increasing the specificity of the results.
The study has also some limitations. First, it was not specifically
designed to test the validity of the PAUSS nor to apply it as a
measure of ASD symptoms. Second, some domains of social cog-
nition that are typically impaired in people diagnosed with schizo-
phrenia, such as attributional style bias and social perception were
not included in the assessment of social cognition. Third, given the
cross-sectional design of the present study, no prospective obser-
vation was performed; therefore, no longitudinal evaluation of the
course and trajectory of ASD symptoms in people diagnosed with
schizophrenia could be made. This did not allow to further con-
tribute to the debate regarding the nature of ASD symptoms in
schizophrenia as a state or trait variable. Finally, no evaluation of
the effect of treatment on ASD symptoms was performed.
Beyond these limitations, the results of this study strengthen the
notion of the relevant impact of ASD symptoms on different aspects
of the disease, crucial to the life of people diagnosed with schizo-
phrenia, and suggest that prominent ASD symptoms could char-
acterize a subpopulation of individuals with SSD.
Future studies should focus on observing the course of ASD
symptoms in people diagnosedwith schizophrenia in a longitudinal
perspective, on evaluating the effects of different treatments on
ASD symptoms and on assessing the presence of ASD symptoms in
relatives of people diagnosed with schizophrenia in order to esti-
mate the familial component of a possible autistic phenotype of
schizophrenia. Even more important from a clinical point of view
could be to analyze whether individuals identified on the basis of
different severity of PAUSS could have different response to phar-
macologic treatment or to specific psychosocial interventions.
Financial Support. This research received no specific grant from any funding
agency, commercial or not-for-profit sectors.
Conflicts of Interest. The authors declared no conflicts of interest.
Data availability Statement. Data that support the findings of this study are
not available.
Ethical Statement. The authors assert that all procedures contributing to this
work comply with the ethical standards of the relevant national and institutional
committees on human experimentation and with the Helsinki Declaration of
1975, as revised in 2008. All patients provided written informed consent to
participate after receiving a comprehensive explanation of study procedures and
goals. The study protocol was approved by the Ethical Committee of the
coordinating center and of the other participating centers (approval number
73/2012).
References
[1] American Psychiatric Association. Diagnostic and statistical manual of
mental disorders (DSM-5®). Arlington, VA: American Psychiatric Asso-
ciation, 2013.
[2] Barlati S, Deste G, Ariu C, Vita A. Autism spectrum disorder and schizo-
phrenia: do they overlap? Int J Emerg Ment Health Hum Resil. 2016;18:
760–3. doi: 10.4172/1522-4821.1000318.
[3] Dell’Osso L, Luche RD, Maj M. Adult autism spectrum as a transnoso-
graphic dimension. CNS Spectr. 2016;21:131–3. doi: 10.1017/
S1092852915000450.
[4] Hommer RE, Swedo SE. Schizophrenia and autism-related disorders.
Schizophr Bull. 2015;41:313–4. doi: 10.1093/schbul/sbu188.
[5] King BH, Lord C. Is schizophrenia on the autism spectrum? Brain Res.
2011;1380:34–41. doi: 10.1016/j.brainres.2010.11.031.
[6] Vannucchi G,Masi G, Toni C, Dell’Osso L,Marazziti D, Perugi G. Clinical
features, developmental course, and psychiatric comorbidity of adult
autism spectrum disorders. CNS Spectr. 2014;19:157–64. doi: 10.1017/
S1092852913000941.
[7] Barlati S, Minelli A, Ceraso A, Nibbio G, Silva RC, Deste G, et al. Social
cognition in a research domain criteria perspective: a bridge between
schizophrenia and autism spectra disorders. Front Psychiatry. 2020;11:
doi: 10.3389/fpsyt.2020.00806.
[8] Bleuler E. Dementia praecox or the group of schizophrenias. Oxford, UK:
International Universities Press, 1911.
[9] Lai M-C, Lombardo MV, Baron-Cohen S. Autism. Lancet Lond Engl.
2014;383:896–910. doi: 10.1016/S0140-6736(13)61539-1.
[10] Pinkham AE, Morrison KE, Penn DL, Harvey PD, Kelsven S, Ludwig K,
et al. Comprehensive comparison of social cognitive performance in
European Psychiatry 7
autism spectrum disorder and schizophrenia. Psychol Med. 2019;1–9. doi:
10.1017/S0033291719002708.
[11] Carroll LS, Owen MJ. Genetic overlap between autism, schizophrenia and
bipolar disorder. Genome Med. 2009;1:102doi: 10.1186/gm102.
[12] de Lacy N, King BH. Revisiting the relationship between autism and
schizophrenia: toward an integrated neurobiology. Annu Rev Clin Psy-
chol. 2013;9:555–87. doi:10.1146/annurev-clinpsy-050212-185627.
[13] Eack SM, Bahorik AL, McKnight SAF, Hogarty SS, Greenwald DP, New-
hill CE, et al. Commonalities in social and non-social cognitive impair-
ments in adults with autism spectrum disorder and schizophrenia.
Schizophr Res. 2013;148:24–8. doi: 10.1016/j.schres.2013.05.013.
[14] Kushima I, Aleksic B, Nakatochi M, Shimamura T, Okada T, Uno Y,
et al. Comparative analyses of copy-number variation in autism
spectrum disorder and schizophrenia reveal etiological overlap and
biological insights. Cell Rep. 2018;24:2838–56. doi: 10.1016/j.celrep.
2018.08.022.
[15] Rapoport J, Chavez A, Greenstein D, Addington A, Gogtay N. Autism-
spectrum disorders and childhood onset schizophrenia: clinical and bio-
logical contributions to a relationship revisited. J Am Acad Child Adolesc
Psychiatry. 2009;48:10–8. doi: 10.1097/CHI.0b013e31818b1c63.
[16] Crescenzo FD, Postorino V, Siracusano M, Riccioni A, Armando M,
Curatolo P, et al. Autistic symptoms in schizophrenia spectrum disorders:
a systematic review and meta-analysis. Front Psychiatry. 2019;10:doi:
10.3389/fpsyt.2019.00078.
[17] Kincaid DL, Doris M, Shannon C, Mulholland C. What is the prevalence
of autism spectrum disorder and ASD traits in psychosis? A systematic
review. Psychiatry Res. 2017;250:99–105. doi: 10.1016/j.psychres.2017.
01.017.
[18] Deste G, Vita A, Penn DL, Pinkham AE, Nibbio G, Harvey PD. Autistic
symptoms predict social cognitive performance in patients with
schizophrenia. Schizophr Res. 2020;215:113–119. doi: 10.1016/j.schres.
2019.11.008.
[19] Harvey PD, Deckler E, Jones MT, Jarskog LF, Penn DL, Pinkham AE.
Autism symptoms, depression, and active social avoidance in schizophre-
nia: association with self-reports and informant assessments of everyday
functioning. J Psychiatr Res. 2019;115:36–42. doi: 10.1016/j.jpsy-
chires.2019.05.010.
[20] Barlati S, Deste G, Gregorelli M, Vita A. Autistic traits in a sample of adult
patients with schizophrenia: prevalence and correlates. PsycholMed. 2019;
49:140–8. doi: 10.1017/S0033291718000600.
[21] Downs JM, Lechler S, Dean H, Sears N, Patel R, Shetty H, et al. The
association between co-morbid autism spectrum disorders and antipsy-
chotic treatment failure in early-onset psychosis: a historical cohort study
using electronic health records. J Clin Psychiatry. 2017;78:e1233–41. doi:
10.4088/JCP.16m11422.
[22] Lord C, Rutter M, Goode S, Heemsbergen J, Jordan H, Mawhood L, et al.
Autism diagnostic observation schedule: a standardized observation of
communicative and social behavior. J Autism Dev Disord. 1989;19:
185–212. doi: 10.1007/bf02211841.
[23] Lord C, Rutter M, Le Couteur A. Autism diagnostic interview-revised: a
revised version of a diagnostic interview for caregivers of individuals with
possible pervasive developmental disorders. J AutismDevDisord. 1994;24:
659–85. doi: 10.1007/bf02172145.
[24] Kästner A, Begemann M, Michel TM, Everts S, Stepniak B, Bach C, et al.
Autism beyond diagnostic categories: characterization of autistic pheno-
types in schizophrenia. BMC Psychiatry. 2015;15:115. doi: 10.1186/
s12888-015-0494-x.
[25] Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale
(PANSS) for schizophrenia. Schizophr Bull. 1987;13:261–76.
[26] Deste G, Barlati S, Gregorelli M, Lisoni J, Turrina C, Valsecchi P, et al.
Looking through autistic features in schizophrenia using the PANSS
Autism Severity Score (PAUSS). Psychiatry Res. 2018;270:764–8. doi:
10.1016/j.psychres.2018.10.074.
[27] Galderisi S, Rucci P, Kirkpatrick B, Mucci A, Gibertoni D, Rocca P, et al.
Interplay among psychopathologic variables, personal resources, context-
related factors, and real-life functioning in individuals with schizophrenia:
a network analysis. JAMA Psychiatry. 2018;75:396–404. doi: 10.1001/
jamapsychiatry.2017.4607.
[28] Galderisi S, Rossi A, Rocca P, Bertolino A, Mucci A, Bucci P, et al. The
influence of illness-related variables, personal resources and context-
related factors on real-life functioning of people with schizophrenia.
World Psychiatry Off J World Psychiatr Assoc WPA. 2014;13:275–87.
doi: 10.1002/wps.20167.
[29] American Psychiatric Association. Diagnostic and statistical manual of
mental disorders. 4th ed. Text revision (DSM-IV-TR). Washington, DC:
American Psychiatric Association, 2000.
[30] First MB, Spitzer RL, Gibbon M, Williams JBW. Structured clinical
interview for DSM-IV® axis I disorders (SCID-I), research version, patient
edition (SCID-I/P W). New York: Biometrics Research, New York State
Psychiatric Institute, 2002.
[31] Nuechterlein KH, Green MF, Kern RS, Baade LE, Barch DM, Cohen JD,
et al. The MATRICS consensus cognitive battery, part 1: test selection,
reliability, and validity. Am J Psychiatry. 2008;165:203–13. doi: 10.1176/
appi.ajp.2007.07010042.
[32] Nuechterlein KH, Green MF. MATRICS consenus cognitive battery man-
ual. Los Angeles, CA: National Institute of Mental Health and University
of California, 2006.
[33] Mausbach BT, Harvey PD, Goldman SR, Jeste DV, Patterson TL. Devel-
opment of a brief scale of everyday functioning in persons with serious
mental illness. Schizophr Bull. 2007;33:1364–72. doi: 10.1093/schbul/
sbm014.
[34] Schneider LC, Struening EL. SLOF: a behavioral rating scale for assessing
the mentally ill. Soc Work Res Abstr. 1983;19:9–21.
[35] Mucci A, Rucci P, Rocca P, Bucci P, Gibertoni D, Merlotti E, et al. The
Specific Level of Functioning Scale: construct validity, internal consistency
and factor structure in a large Italian sample of people with schizophrenia
living in the community. Schizophr Res. 2014;159:144–50. doi: 10.1016/j.
schres.2014.07.044.
[36] Chung YS, Barch D, Strube M. A meta-analysis of mentalizing impair-
ments in adults with schizophrenia and autism spectrum disorder. Schi-
zophr Bull. 2014;40:602–16. doi: 10.1093/schbul/sbt048.
[37] Eack SM, Wojtalik JA, Keshavan MS, Minshew NJ. Social-cognitive brain
function and connectivity during visual perspective-taking in autism
and schizophrenia. Schizophr Res. 2017;183:102–9. doi: 10.1016/j.
schres.2017.03.009.
[38] Martinez G, Alexandre C, Mam-Lam-Fook C, Bendjemaa N, Gaillard R,
Garel P, et al. Phenotypic continuum between autism and schizophrenia:
evidence from the Movie for the Assessment of Social Cognition (MASC).
Schizophr Res. 2017;185:161–6. doi: 10.1016/j.schres.2017.01.012.
[39] Ehrenreich H, Mitjans M, Van der Auwera S, Centeno TP, Begemann M,
Grabe HJ, et al. OTTO: a new strategy to extract mental disease-relevant
combinations of GWAS hits from individuals. Mol Psychiatry. 2018;23:
476–86. doi: 10.1038/mp.2016.208.
[40] Stepniak B, Kästner A, Poggi G, Mitjans M, Begemann M, Hartmann A,
et al. Accumulated common variants in the broader fragile X gene family
modulate autistic phenotypes. EMBO Mol Med. 2015;7:1565–79. doi:
10.15252/emmm.201505696.
[41] Oliveira B, Mitjans M, Nitsche MA, Kuo M-F, Ehrenreich H. Excitation-
inhibition dysbalance as predictor of autistic phenotypes. J Psychiatr Res.
2018;104:96–9. doi: 10.1016/j.jpsychires.2018.06.004.
[42] Parellada M, Pina-Camacho L, Moreno C, Aleman Y, Krebs M-O, Desco
M, et al. Insular pathology in young people with high-functioning autism
and first-episode psychosis. Psychol Med. 2017;47:2472–82. doi: 10.1017/
S0033291717000988.
Appendix
Members of the Italian Network for Research on Psychoses involved in this
study include: Anna Ceraso, Alessandro Galluzzo, Jacopo Lisoni (University of
Brescia); Piergiuseppe Di Palo, Marco Papalino, Raffaella Romano (University
of Bari); Federica Pinna, Alice Lai, Silvia Lostia di Santa Sofia (University of
Cagliari); Paola Bucci, Giuseppe Piegari, Francesco Brando, Luigi Giuliani
(University of Campania “L. Vanvitelli,” Naples); Maria Salvina Signorelli,
Laura Fusar Poli (University of Catania); Giovanni Martinotti, Mauro Pettor-
ruso, Chiara Montemitro (University of Chieti); Mario Altamura, Stefania
8 Antonio Vita et al.
Malerba, Flavia Padalino (University of Foggia); Andrea Amerio, Pietro Cal-
cagno, Domenico Zampogna (University of Genoa); Laura Giusti, Anna Salza,
Silvia Mammarella, Francesca Pacitti, Valentina Socci, Dalila Talevi (University
of L’Aquila); Carla Gramaglia, Alessandro Feggi, Amalia Jona (University of
Eastern Piedmont, Novara); Angela Favaro, Elena Tenconi, Paolo Meneguzzo
(University of Padua); Paolo Ossola, Matteo Tonna, Maria Lidia Gerra
(University of Parma); Claudia Carmassi, Camilla Gesi, Barbara Carpita
(University of Pisa); Giulio Corrivetti, Giammarco Cascino, Gianfranco del
Buono (Department of Mental Health, Salerno); Fabio Di Fabio, Antonio
Buzzanca, Nicoletta Girardi, Roberto Brugnoli, Anna Comparelli, Valentina
Corigliano (Sapienza University of Rome); Andrea Fagiolini, Simone Bolognesi,
Arianna Goracci (University of Siena); Giorgio Di Lorenzo, Cinzia Niolu,
Michele Ribolsi (Tor Vergata University of Rome); Claudio Brasso, Cecilia
Riccardi, Elisa Del Favero (University of Turin).
European Psychiatry 9
